rss
Occup Environ Med 62:231-236 doi:10.1136/oem.2004.015628
  • Original article

Cancer risks in a historical UK cohort of benzene exposed workers

Table 6

 Cancer incidence in benzene exposed workers (4740 males, 352 females)*, 1971–2001

Site of cancer ICD-9 Obs Exp SRR† (95% CI)
*Excludes untraced workers and pre-1971 deaths and embarkations.
†SRRs and confidence intervals based on expectations calculated to two places of decimals.
‡Excluding other skin (ICD-9 173).
§Acute non-lymphocytic leukaemia (see footnote to table 3).
All malignant neoplasms‡ 140–208 986 923.1 107 (100 to 114)
    Lip 140 3 2.2 138 (28 to 402)
    Tongue 141 2 3.8 53 (6 to 191)
    Salivary gland 142 0 1.9 0 (0 to 190)
    Mouth 143–145 7 4.8 145 (58 to 299)
    Pharynx 146–149 3 6.8 44 (9 to 130)
    Oesophagus 150 16 26.2 61 (35 to 99)
    Stomach 151 67 61.5 109 (84 to 138)
    Small intestine 152 2 2.1 97 (12 to 351)
    Large intestine 153 60 70.0 86 (65 to 110)
    Rectum 154 61 54.0 113 (86 to 145)
    Liver 155.0, 155.1 8 6.1 131 (57 to 259)
    Gallbladder 156 3 4.6 66 (14 to 192)
    Pancreas 157 36 27.9 129 (90 to 179)
    Peritoneum 158 3 1.2 246 (51 to 719
    Other digestive 159 3 1.6 184 (38 to 538)
    Nose and sinuses 160 1 2.1 47 (1 to 262)
    Larynx 161 12 15.1 79 (41 to 138)
    Lung and bronchus 162 293 245.3 119 (106 to 134)
    Pleura 163 15 6.3 237 (133 to 391)
    Bone 170 1 1.4 73 (2 to 407)
    Connective tissue 171 2 4.0 50 (6 to 182)
    Melanoma 172 13 10.7 121 (64 to 207)
    Breast 175 15 16.7 90 (50 to 149)
    Cervix 180 1 2.0 50 (1 to 279)
    Uterus 182 2 2.2 89 (11 to 323)
    Ovary 183 3 2.8 108 (22 to 317)
    Other genital 184, 187 7 3.5 202 (81 to 416)
    Prostate 185 121 109.9 110 (91 to 132)
    Testis 186 1 3.7 27 (1 to 149)
    Bladder 188 69 66.6 104 (81 to 131)
    Kidney 189.0 16 17.8 90 (51 to 146)
    Other urinary 189.1–189.9 3 3.3 92 (19 to 268)
    Eye 190 1 1.7 58 (1 to 324)
    Brain 191–192 18 15.6 116 (68 to 183)
    Thyroid 193 0 2.1 0 (0 to 174)
    Other endocrine glands 194 1 0.8 122 (3 to 679)
    Secondary and unspecified 195–199 54 49.0 110 (83 to 144)
    Hodgkin’s disease 201 2 4.4 45 (5 to 163)
    Non-Hodgkin’s lymphoma 200, 202 24 24.0 100 (64 to 149)
    Multiple myeloma 203 8 11.8 68 (29 to 134)
    Leukaemia 204–208 25 20.9 120 (78 to 177)
        ANLL§ 205.0, 206.0, 207.0, 208.0 12 7.3 165 (85 to 288)
        Other leukaemia rem. 204–208 13 13.6 96 (51 to 164)

This Article

Free sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of OEM.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.